GO:0034345 negative regulation of type III interferon production: Immune Evasion Mechanism, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0034345 describes any process that stops, prevents, or reduces the production of type III interferons, of which interferon lambda (IFN-λ) is the only known member.
• Type III interferon production is activated downstream of pattern-recognition receptors such as RIG-I and TBK1-IRF3 signaling, and its negative regulation often converges on this axis.
• NSUN2-mediated m5C methylation of IRF3 mRNA exemplifies an RNA-modification layer that suppresses interferon responses, including type III IFN.
• Hypoxia and glucocorticoid activation are physiological contexts that repress interferon induction in intestinal epithelium and melanoma, respectively.
• Pathogenic bacteria can activate type III interferon genes in epithelial cells and placenta, showing that the pathway is not restricted to antiviral immunity.
• Dysregulated negative regulation of type III IFN contributes to delayed respiratory virus clearance, suboptimal vaccine responses, and altered blood-brain barrier integrity during JEV infection.
Description
Type III interferons, also known as interferon lambdas (IFN-λ), constitute a distinct family of antiviral cytokines that signal through the IFNLR1/IL10RB receptor complex and are produced predominantly by epithelial cells and some immune cells. The Gene Ontology term GO:0034345, negative regulation of type III interferon production, captures the cellular processes that stop, prevent, or reduce the frequency, rate, or extent of IFN-λ production. Because IFN-λ is the only member of the type III interferon family identified so far, this term effectively describes the negative control of IFN-λ synthesis at transcriptional, post-transcriptional, and signaling levels. Negative regulation of type III interferon production is critical for balancing antiviral defense against immunopathology. Excessive IFN-λ can drive epithelial barrier dysfunction and inflammation, whereas insufficient IFN-λ leads to delayed viral clearance and impaired vaccine responses. Multiple intracellular checkpoints, including TBK1-IRF3 signaling, RNA methylation, and E3 ubiquitin ligase activity, converge to suppress type III IFN production. Understanding these checkpoints is essential for researchers studying host-pathogen interactions, mucosal immunity, and therapeutic modulation of interferon responses. This article integrates the QuickGO definition of GO:0034345 with verified PubMed literature to provide a research-grade overview of the genes, mechanisms, disease links, and experimental models relevant to negative regulation of type III interferon production. It is intended for scientists designing CRISPR knockout, knock-in, or overexpression studies to dissect this pathway.
negative regulation of type III interferon production At A Glance
| GO ID | GO:0034345 |
|---|---|
| GO term | negative regulation of type III interferon production |
| Ontology | biological_process |
| Synonym | down regulation of type III interferon production; down-regulation of type III interferon production; downregulation of type III interferon production; inhibition of type III interferon production; negative regulation of type III IFN production |
| Major function | Suppression of interferon lambda (IFN-λ) production, thereby modulating antiviral and immune responses |
| Definition source | QuickGO definition: Any process that stops, prevents, or reduces the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon found so far. |
| Related processes | Negative regulation of type I interferon production; RIG-I signaling; TBK1-IRF3 signaling; RNA methylation |
| Cellular context | Epithelial cells, immune cells, and placental cells; often studied in viral and bacterial infection models |
What Is GO:0034345?
GO:0034345, negative regulation of type III interferon production, is a biological process defined as any process that stops, prevents, or reduces the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon family found so far. This term encompasses both direct inhibition of IFN-λ gene transcription and indirect mechanisms that dampen the signaling cascades leading to IFN-λ synthesis, such as negative regulation of TBK1-IRF3 signaling or RNA modification of IRF3 transcripts.
Why Is negative regulation of type III interferon production Important in Cell Biology?
Negative regulation of type III interferon production is important because it determines the magnitude and duration of mucosal antiviral responses. IFN-λ acts primarily on epithelial barriers, and its overproduction can cause tissue damage, while its insufficient production leads to delayed viral clearance and poor vaccine responses. Moreover, pathogens and tumors exploit negative regulators of type III IFN to evade immunity, making this process a target for therapeutic intervention. Understanding GO:0034345 helps researchers identify host factors that can be modulated to enhance or dampen IFN-λ responses in infectious disease, cancer, and inflammatory conditions.
• Controls the intensity of antiviral defense at epithelial barriers, affecting respiratory virus clearance and vaccine efficacy.
• Regulates immune evasion by pathogens that suppress IFN-λ production to establish infection.
• Modulates the tumor microenvironment and response to PD-1 blockade in melanoma through glucocorticoid-mediated interferon suppression.
• Influences blood-brain barrier integrity during Japanese encephalitis virus infection via type I/type III IFN regulation.
• Provides a mechanistic link between RNA modifications (m5C) and interferon gene expression.
• Involves E3 ubiquitin ligases such as TRIM48 that negatively regulate RIG-I signaling and downstream IFN production.
• Is relevant to autoimmune and inflammatory diseases where excessive or insufficient IFN-λ contributes to pathology.
• Offers targets for host-directed therapies that modulate interferon responses without causing broad immunosuppression.
• Guides design of CRISPR screens to identify novel negative regulators of type III IFN production.
• Helps interpret inter-individual differences in susceptibility to respiratory and enteric viral infections.
What Happens During negative regulation of type III interferon production?
Initiation of type III interferon production
In simple terms: Cells sense viral or bacterial components and start a signaling chain that turns on IFN-λ genes.
Type III interferon production is initiated when pattern-recognition receptors detect pathogen-associated molecular patterns. In epithelial cells, RIG-I-like receptors activate TBK1 and IRF3, leading to transcription of IFNL genes. Pathogenic bacteria can also activate type III interferon genes in infected epithelial cells and mouse placenta, indicating that both viral and bacterial stimuli converge on IFN-λ induction. This initiation step is the primary target of negative regulatory mechanisms.
Negative regulation at the signaling level
In simple terms: Brakes are applied to the signaling molecules that would otherwise turn on IFN-λ.
Negative regulation of type III interferon production frequently occurs through inhibition of TBK1-IRF3 signaling. STK4 deficiency impairs innate immunity and interferon production through negative regulation of TBK1-IRF3 signaling, demonstrating that STK4 normally restrains this pathway. Similarly, the E3 ubiquitin ligase TRIM48 acts as a novel negative regulator of RIG-I signaling, thereby limiting downstream interferon production. These signaling checkpoints prevent excessive IFN-λ synthesis during infection.
Post-transcriptional and epigenetic control
In simple terms: Chemical marks on RNA or DNA can shut down interferon production after the signal has started.
NSUN2-mediated m5C methylation of IRF3 mRNA negatively regulates type I interferon responses during various viral infections, and this mechanism also affects type III interferon production because IRF3 is a shared transcription factor. This RNA modification reduces IRF3 protein levels, thereby dampening IFN-λ gene transcription. Such post-transcriptional control provides a rapid and reversible layer of negative regulation.
Physiological and environmental repression
In simple terms: Conditions like low oxygen or stress hormones can suppress interferon production.
Hypoxia increases susceptibility of human intestinal epithelial cells to rotavirus infection through repression of interferon induction, including type III IFN. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma, showing that hormonal signals can negatively regulate interferon production. These physiological contexts illustrate how the microenvironment shapes IFN-λ output.
Consequences for viral clearance and immunity
In simple terms: When IFN-λ is suppressed, viruses may persist longer and vaccines may work less well.
Limited nasal IFN production contributes to delayed respiratory virus clearance and suboptimal vaccine responses, highlighting the clinical impact of insufficient type III IFN. In Japanese encephalitis virus infection, type I/type III IFN and related factors regulate infection and blood-brain barrier endothelial integrity, indicating that negative regulation of IFN-λ can influence neuroinvasion. Thus, the balance of positive and negative regulation determines disease outcome.
Key Genes Involved in GO:0034345 negative regulation of type III interferon production
The following genes and proteins are experimentally implicated in the negative regulation of type III interferon production or in the signaling pathways that this process controls.
| Gene | Major Role | Research Relevance |
|---|---|---|
| IRF3 | Transcription factor that induces IFN-λ genes; target of negative regulation | Central node for studying transcriptional control of type III IFN |
| TBK1 | Kinase that activates IRF3; inhibited by negative regulators | Key checkpoint for pharmacological and genetic manipulation |
| STK4 | Negative regulator of TBK1-IRF3 signaling; deficiency impairs IFN production | Loss-of-function models show enhanced IFN responses |
| NSUN2 | RNA methyltransferase that deposits m5C on IRF3 mRNA, reducing IRF3 levels | Epitranscriptomic regulation of IFN production |
| TRIM48 | E3 ubiquitin ligase that negatively regulates RIG-I signaling | Target for CRISPR knockout to boost IFN production |
| RIG-I (DDX58) | Cytosolic sensor that initiates IFN induction; subject to negative regulation | Upstream control point for type III IFN |
| HSD11B1 | Enzyme that activates glucocorticoids, limiting T cell-driven IFN signaling | Links steroid metabolism to IFN suppression in melanoma |
| IFNL1 (IL29) | Type III interferon ligand; its production is the endpoint of regulation | Direct readout of GO:0034345 activity |
| IFNL2/IFNL3 | Type III interferon ligands co-regulated with IFNL1 | Genetic variants affect viral clearance and treatment response |
| IFNLR1 | Receptor subunit for IFN-λ; downstream of production | Determines sensitivity to autocrine/paracrine IFN-λ |
| IL10RB | Shared receptor subunit for IFN-λ signaling | Modulates feedback regulation of IFN production |
| STAT1 | Transcription factor downstream of IFN-λ receptor; mediates feedback | Feedback inhibition of IFN production |
| STAT2 | Part of ISGF3 complex downstream of IFN-λ | Feedback and amplification loops |
| IRF9 | Part of ISGF3 complex; mediates IFN-stimulated gene expression | Feedback regulation of type III IFN |
| NF-κB subunits | Transcription factors that cooperate with IRF3 for IFN-λ induction | Integration of inflammatory signals |
| MAVS | Mitochondrial adaptor in RIG-I signaling; target of negative regulation | Upstream checkpoint for IFN production |
| SOCS proteins | Feedback inhibitors of cytokine signaling | Potential negative regulators of IFN-λ production |
| USP proteins | Deubiquitinases that can stabilize or destabilize signaling components | Emerging regulators of IFN pathways |
How Is negative regulation of type III interferon production Regulated?
Negative regulation of type III interferon production is controlled at multiple levels. At the signaling level, STK4 restrains TBK1-IRF3 signaling, and its deficiency leads to enhanced interferon production. The E3 ubiquitin ligase TRIM48 negatively regulates RIG-I signaling, thereby limiting downstream IFN-λ induction. At the post-transcriptional level, NSUN2-mediated m5C methylation of IRF3 mRNA reduces IRF3 protein levels and dampens interferon responses. Physiologically, hypoxia represses interferon induction in intestinal epithelial cells, increasing susceptibility to rotavirus, while glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling in melanoma. These diverse mechanisms ensure that IFN-λ production is tightly controlled to avoid tissue damage while maintaining antiviral defense.
negative regulation of type III interferon production and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| HSD11B1 | Melanoma immunotherapy resistance | HSD11B1 knockout or overexpression in melanoma cell lines and T cell co-cultures |
| STK4 | Immunodeficiency and impaired interferon production | STK4 knockout in epithelial or immune cells followed by viral infection |
| NSUN2 | Viral infection and interferon suppression | NSUN2 knockout or point mutation to assess IRF3 m5C and IFN-λ levels |
| TRIM48 | RIG-I signaling and antiviral immunity | TRIM48 overexpression or knockout in reporter cells |
| IFNL1/IFNL3 | Respiratory viral clearance and vaccine response | Knock-in of human IFNL variants in mouse models |
Respiratory viral infections and vaccine responses
Limited nasal IFN production, including type III IFN, contributes to delayed respiratory virus clearance and suboptimal vaccine responses. Negative regulation of type III interferon production in the nasal mucosa may therefore be a determinant of susceptibility to respiratory viruses and of vaccine efficacy. Therapeutic strategies that transiently reduce negative regulation could enhance local IFN-λ and improve outcomes.
Melanoma and cancer immunotherapy
Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. This suggests that negative regulation of type III interferon production in the tumor microenvironment can impair antitumor immunity and immunotherapy efficacy. Targeting HSD11B1 or downstream negative regulators might restore IFN-λ production and improve checkpoint blockade responses.
Enteric viral infections and intestinal barrier function
Hypoxia increases susceptibility of human intestinal epithelial cells to rotavirus infection through repression of interferon induction, including type III IFN. Negative regulation of type III interferon production in the gut epithelium may thus exacerbate enteric viral infections. Modulating oxygen-sensing pathways or IFN-λ production could protect against rotavirus and other enteric pathogens.
Neuroinflammation and blood-brain barrier integrity
Type I/type III IFN and related factors regulate Japanese encephalitis virus infection and blood-brain barrier endothelial integrity. Negative regulation of type III interferon production may influence neuroinvasion and neuroinflammation. Understanding these mechanisms could inform therapies for viral encephalitis and other CNS infections.
From negative regulation of type III interferon production-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does a candidate gene negatively regulate type III IFN production? | CRISPR knockout in epithelial cell lines (e.g., A549, HT-29) followed by poly(I:C) or viral infection and IFN-λ ELISA |
| Does a specific point mutation in IRF3 affect its m5C modification and stability? | Point-mutation knock-in of IRF3 at the NSUN2 target site |
| Can overexpression of a negative regulator suppress IFN-λ in vivo? | Transgenic or viral-vector overexpression in mouse nasal mucosa or intestine |
| What is the dynamics of IFN-λ production after negative regulator loss? | Tagged knock-in of IFNL1 with luciferase or fluorescent reporter |
| Which E3 ligases regulate RIG-I and type III IFN? | CRISPR library screening for E3 ubiquitin ligases in IFN reporter cells |
| How does hypoxia affect type III IFN production? | Hypoxia chamber experiments with intestinal epithelial cells and rotavirus infection |
How to Study the negative regulation of type III interferon production Process
| Method | What It Measures | Typical Application |
|---|---|---|
| RNA-seq | Global transcriptome changes, including IFNL genes | Identifying negative regulators of IFN-λ production |
| qRT-PCR | Specific IFN-λ mRNA levels | Validating knockout or overexpression effects |
| ELISA | Secreted IFN-λ protein | Quantifying functional IFN-λ production |
| Western blot | Phospho-TBK1, IRF3 dimerization, protein stability | Assessing signaling checkpoint activity |
| Luciferase reporter | IFNL promoter activity | High-throughput screening of regulatory factors |
| m5C RNA IP | NSUN2-dependent methylation on IRF3 mRNA | Studying epitranscriptomic regulation |
| CRISPR library screen | Fitness or reporter activation after gene knockout | Discovery of novel negative regulators |
| In vivo infection model | Viral clearance, IFN-λ levels, vaccine response | Translational studies of type III IFN regulation |
Transcriptional and post-transcriptional profiling
RNA-seq and targeted qPCR can quantify IFNL1, IFNL2, and IFNL3 mRNA levels after genetic perturbation. To study negative regulation, researchers compare IFN-λ transcript levels in knockout versus wild-type cells following viral infection or poly(I:C) stimulation. Additionally, m5C RNA immunoprecipitation and sequencing can map NSUN2-dependent methylation on IRF3 mRNA.
Protein-level and signaling assays
Western blotting and immunoprecipitation are used to assess TBK1 phosphorylation, IRF3 dimerization, and IRF3 protein stability. STK4 and TRIM48 effects on TBK1-IRF3 signaling can be measured by phospho-specific antibodies. Luciferase reporter assays driven by the IFNL1 promoter provide a quantitative readout of transcriptional activity.
Functional antiviral and vaccine models
In vivo models, such as mouse nasal infection or vaccination, can measure IFN-λ levels in mucosal secretions and correlate them with viral clearance and antibody responses. Rotavirus infection of intestinal epithelial cells under hypoxia is used to study repression of interferon induction. Melanoma models with T cell co-cultures assess how glucocorticoid activation limits IFN signaling and PD-1 blockade efficacy.
CRISPR screening and bioinformatics
High-throughput CRISPR knockout screens targeting E3 ubiquitin ligases or kinases can identify novel negative regulators of type III IFN production. Bioinformatics analysis of RNA-seq and ATAC-seq data can reveal regulatory networks and transcription factor binding sites in IFNL gene promoters. These approaches are complemented by pathway enrichment using GO terms such as GO:0034345.
How CRISPR Can Be Used to Study GO:0034345 negative regulation of type III interferon production
Knockout
CRISPR knockout of candidate negative regulators such as STK4, TRIM48, or NSUN2 can be used to test whether loss of function enhances type III interferon production. For example, STK4 deficiency impairs innate immunity and interferon production through negative regulation of TBK1-IRF3 signaling, so STK4 knockout cells may show increased IFN-λ upon viral challenge. Similarly, TRIM48 knockout may boost RIG-I signaling and downstream IFN-λ.
Point Mutation
Point mutations can dissect specific residues required for negative regulation. For instance, mutating the m5C site in IRF3 mRNA or the catalytic residue of NSUN2 can reveal how RNA methylation controls IRF3 stability and IFN-λ production. Point mutations in TBK1 phosphorylation sites can clarify how STK4 restrains signaling.
Knock-in
Knock-in of reporter cassettes (e.g., luciferase or fluorescent protein) into the IFNL1 locus enables real-time monitoring of type III interferon production in live cells and animals. Knock-in of human IFNL variants can model genetic differences in IFN-λ production and viral clearance. Tagged knock-in of IRF3 allows tracking of its modification and localization.
Overexpression
Overexpression of negative regulators such as HSD11B1, TRIM48, or NSUN2 can suppress type III interferon production and mimic pathological states. For example, HSD11B1 overexpression limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma. Overexpression studies help establish sufficiency of a candidate gene in negative regulation.
How EDITGENE Supports negative regulation of type III interferon production Research
Researchers studying negative regulation of type III interferon production-related genes often need to determine whether a candidate gene is causally involved in suppressing IFN-λ, and whether this suppression affects viral clearance, vaccine responses, or tumor immunity. EDITGENE provides CRISPR-based cell model services to enable these causal experiments with high precision and reproducibility.
Contact EDITGENE today to design your custom CRISPR model for negative regulation of type III interferon production research.
Frequently Asked Questions About negative regulation of type III interferon production
What is GO:0034345?
GO:0034345 is the Gene Ontology term for negative regulation of type III interferon production, defined as any process that stops, prevents, or reduces the frequency, rate, or extent of type III interferon production. Interferon lambda is the only member of the type III interferon family found so far.
What is type III interferon?
Type III interferon, or interferon lambda (IFN-λ), is a family of antiviral cytokines that signal through the IFNLR1/IL10RB receptor complex and are produced mainly by epithelial cells.
What genes are involved in negative regulation of type III interferon production?
Genes such as STK4, TRIM48, NSUN2, HSD11B1, and IRF3 have been implicated in negatively regulating type III interferon production or its upstream signaling.
How is type III interferon production negatively regulated?
Negative regulation occurs at multiple levels, including inhibition of TBK1-IRF3 signaling by STK4, ubiquitination of RIG-I by TRIM48, m5C methylation of IRF3 mRNA by NSUN2, and physiological repression by hypoxia or glucocorticoids.
Why is negative regulation of type III interferon production important for viral infections?
It determines the magnitude and duration of mucosal antiviral responses; insufficient IFN-λ leads to delayed viral clearance and suboptimal vaccine responses.
Can CRISPR be used to study negative regulation of type III interferon production?
Yes, CRISPR knockout, point mutation, knock-in, and overexpression models allow causal testing of candidate genes in this pathway.
What diseases are linked to dysregulated type III interferon production?
Respiratory viral infections, melanoma immunotherapy resistance, rotavirus infection, and Japanese encephalitis virus neuroinvasion have been linked to altered type III IFN regulation.
How do I measure type III interferon production in the lab?
Common methods include ELISA for secreted IFN-λ, qRT-PCR for IFNL mRNA, luciferase reporter assays for promoter activity, and RNA-seq for global transcriptome changes.
What is the role of NSUN2 in type III interferon regulation?
NSUN2 mediates m5C methylation of IRF3 mRNA, which negatively regulates type I interferon responses and also affects type III interferon production because IRF3 is a shared transcription factor.
What experimental models are suitable for studying GO:0034345?
Epithelial cell lines, intestinal organoids, mouse nasal infection models, melanoma co-culture systems, and CRISPR screens are suitable models.
Conclusion
Negative regulation of type III interferon production (GO:0034345) is a critical control point in mucosal immunity, balancing antiviral defense against tissue damage. The pathway involves signaling checkpoints such as STK4 and TRIM48, post-transcriptional control by NSUN2, and physiological repression by hypoxia and glucocorticoids. Dysregulation of this process contributes to delayed viral clearance, impaired vaccine responses, and cancer immunotherapy resistance. CRISPR-based cell models are powerful tools to dissect the causal roles of candidate genes in this pathway. By combining knockout, point mutation, knock-in, and overexpression strategies with functional assays, researchers can identify new therapeutic targets to modulate IFN-λ production in infectious and inflammatory diseases.
References
- 1. Sojati J et al.. 2025. Limited nasal IFN production contributes to delayed respiratory virus clearance and suboptimal vaccine responses.. JCI Insight 10(20) PMID: 40956633
- 2. Wang H et al.. 2023. NSUN2-mediated M(5)c methylation of IRF3 mRNA negatively regulates type I interferon responses during various viral infections.. Emerg Microbes Infect 12(1):2178238 PMID: 36748584
- 3. Jørgensen SE et al.. 2021. STK4 Deficiency Impairs Innate Immunity and Interferon Production Through Negative Regulation of TBK1-IRF3 Signaling.. J Clin Immunol 41(1):109-124 PMID: 33078349
- 4. Martins Nascentes Melo L et al.. 2023. Glucocorticoid activation by HSD11B1 limits T cell-driven interferon signaling and response to PD-1 blockade in melanoma.. J Immunother Cancer 11(4) PMID: 37028818
- 5. Jacobs SO et al.. 2025. Hypoxia increases susceptibility of human intestinal epithelial cells to rotavirus infection through repression of interferon induction.. Gut Microbes 17(1):2560593 PMID: 40977474
- 6. Bierne H et al.. 2012. Activation of type III interferon genes by pathogenic bacteria in infected epithelial cells and mouse placenta.. PLoS One 7(6):e39080 PMID: 22720036
- 7. Wu G et al.. 2025. High-throughput screening of E3 ubiquitin ligases identifies TRIM48 as a novel negative regulator of RIG-I signaling.. Cell Signal 134:111973 PMID: 40609779
- 8. Zhang YG et al.. 2023. Type I/type III IFN and related factors regulate JEV infection and BBB endothelial integrity.. J Neuroinflammation 20(1):216 PMID: 37752509
